A Study to Evaluate LB1148 for Return of Gastrointestinal Function and Adhesions in Subjects Undergoing Bowel Resection

PHASE2CompletedINTERVENTIONAL
Enrollment

112

Participants

Timeline

Start Date

October 1, 2019

Primary Completion Date

September 6, 2023

Study Completion Date

September 8, 2023

Conditions
IleusPost-Operative Adhesions
Interventions
DRUG

LB1148

A total of 700 mL of drug product will be administered orally as a split dose before surgery.

DRUG

Placebo

A total of 700 mL of placebo will be administered orally as a split dose before surgery.

Trial Locations (28)

10029

Site 317, New York

10075

Site 323, New York

15212

Site 322, Pittsburgh

19096

Site 330, Wynnewood

21237

Site 321, Baltimore

27599

Site 318, Chapel Hill

29425

Site 327, Charleston

32804

Site 308, Orlando

33125

Site 303, Miami

33126

Site 331, Miami

33142

Site 305, Miami

33756

Site 306, Clearwater

36617

Site 315, Mobile

40202

Site 328, Louisville

44195

Site 301, Cleveland

55905

Site 325, Rochester

75390

Site 320, Dallas

76104

Site 316, Fort Worth

77024

Site 311, Houston

77030

Site 319, Houston

77089

Sie 309, Houston

84132

Site 326, Salt Lake City

85364

Site 307, Yuma

90502

Site 312, Torrance

91105

Site 310, Pasadena

91342

Site 302, Sylmar

92868

Site 329, Irvine

01850

Site 324, Burlington

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Palisade Bio

INDUSTRY